ClinicalTrials.gg

Program

REGEND001

A development code. Also written as “REGEND001 cell therapy”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Idiopathic Pulmonary Fibrosis, led by Regend Therapeutics.

Furthest: phase 3, since Sep 14, 20264 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regend Therapeutics41 open or runningphase 3since Sep 14, 2026Nov 2, 2022Sep 2028phase 3 · NCT07828353

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2022First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05638776 · 58 enrolled · China
  2. Nov 15, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT05657184 · 12 enrolled · China
  3. Sep 17, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT06081621 · 23 enrolled · China
  4. Sep 14, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07828353 · 102 planned · China

Ahead

  1. Sep 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07828353

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07828353Pulmonary Disease, Chronic Obstructive · China3Not yet recruitingSep 2028102
NCT06081621Idiopathic Pulmonary Fibrosis · China2CompletedMar 14, 202523
NCT05657184Idiopathic Pulmonary Fibrosis · China1CompletedJun 9, 202312
NCT05638776Pulmonary Disease, Chronic Obstructive · China2CompletedJul 9, 202558

How it is read

Names in the registry

  • “REGEND001”, 3 entries
  • “REGEND001 cell therapy”, 1 entry

Codes read as this program: REGEND001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.